The Manufacturers Life Insurance Company Has $592,000 Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

The Manufacturers Life Insurance Company trimmed its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 11.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,043 shares of the company’s stock after selling 8,496 shares during the quarter. The Manufacturers Life Insurance Company owned 0.13% of EyePoint Pharmaceuticals worth $592,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in EYPT. Ameritas Investment Partners Inc. increased its holdings in shares of EyePoint Pharmaceuticals by 44.0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after purchasing an additional 1,136 shares during the period. ProShare Advisors LLC bought a new position in EyePoint Pharmaceuticals during the 1st quarter worth $209,000. Greenwich Wealth Management LLC acquired a new position in EyePoint Pharmaceuticals in the 2nd quarter valued at $94,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of EyePoint Pharmaceuticals by 271.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after acquiring an additional 7,953 shares during the period. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of EyePoint Pharmaceuticals during the 1st quarter worth $230,000. Institutional investors own 99.41% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on EYPT. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Chardan Capital reiterated a “buy” rating and issued a $28.00 target price on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Thursday, June 20th. Finally, Jefferies Financial Group initiated coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.57.

EyePoint Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ EYPT opened at $9.88 on Wednesday. The firm has a market cap of $514.59 million, a PE ratio of -5.43 and a beta of 1.57. The company’s fifty day simple moving average is $8.55 and its 200 day simple moving average is $11.09. EyePoint Pharmaceuticals, Inc. has a 12-month low of $5.67 and a 12-month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The firm had revenue of $9.48 million during the quarter, compared to the consensus estimate of $11.61 million. EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. On average, equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.